P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
B.C. Cho(Yonsei University), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Gargi Patel(AstraZeneca (United Kingdom)), Sarah B. Goldberg(Yale University), J. Elizabeth Pease, Jonathan W. Goldman(University of California, Los Angeles), P. Szekeres(AstraZeneca (Netherlands)), Paul D. Smith(Epworth Hospital), Gail Doughton(AstraZeneca (United Kingdom)), Ilhem Mensi(AstraZeneca (United Kingdom)), Ryan J. Hartmaier(AstraZeneca (United States)), Adrianus J. de Langen(The Netherlands Cancer Institute), Julie Maidment(AstraZeneca (United Kingdom)), Zofia Piotrowska(Global Cancer Institute), Isamu Okamoto(Kyushu University Hospital), Jonathan W. Riess(University of California Davis Medical Center), M. Li(Precision for Medicine (United States)), Xiuning Le(The University of Texas MD Anderson Cancer Center)
Cited by 3
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879